Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

07 nov. 2025 08h45 HE | Source: Neurogastrx

Neurogastrx Announces NG101 Phase 2 Clinical Study Demonstrating Significant Reductions in Nausea and Vomiting Induced by GLP-1 Receptor Agonist Semaglutide

Neurogastrx Announces NG101 Phase 2 Clinical Study Demonstrating Significant Reductions in Nausea & Vomiting Induced by GLP-1 Receptor Agonist Semaglutide
07 oct. 2025 09h00 HE | Source: Neurogastrx

Neurogastrx to Present Proof-of-Concept Clinical Data on Oral Candidate NG101 to Reduce Nausea & Vomiting Associated with GLP-1 Agonists at ObesityWeek®

Neurogastrx to Present Proof-of-Concept Clinical Data on Oral Candidate NG101 to Reduce Nausea & Vomiting Associated with GLP-1 Agonists at ObesityWeek®
04 avr. 2023 06h00 HE | Source: SPHERICAL INSIGHTS LLP

Global Postoperative Nausea and Vomiting Market Size to grow USD 2471.1 Billion By 2030 | CAGR of 3.55%

New York, United States , April 04, 2023 (GLOBE NEWSWIRE) -- The Global Postoperative Nausea and Vomiting Market Size is to grow from USD 1805.6 Million in 2021 to USD 2471.1 million by 2030, at a...